title: In vitro activity of daptomycin against Gram-positive cocci: the first multicentre study in Greece.
abstract: A total of 10420 Gram-positive cocci (including staphylococci, enterococci and various groups of streptococci) collected from clinically significant specimens in ten Greek hospitals during 2006--2007 were tested for their susceptibility to daptomycin. The minimum inhibitory concentration (MIC) was determined by the broth microdilution method. Daptomycin demonstrated very high activity against Enterococcus faecalis (MIC at which 50% of the isolates were inhibited (MIC50) = 1mg/L and MIC at which 90% of the isolates were inhibited (MIC90) = 1.36 mg/L), Enterococcus faecium (MIC50 = 1.36 mg/L and MIC90 = 1.90 mg/L), Streptococcus pyogenes (MIC50 = 0.12 mg/L and MIC90 = 0.50mg/L), Streptococcus agalactiae (MIC50 = 0.09 mg/L and MIC90 = 0.12 mg/L), Streptococcus pneumoniae (MIC50 = 0.24 mg/L and MIC90 = 0.5 mg/L) and viridans group streptococci (MIC50 = 0.50 mg/L and MIC90 = 0.89 mg/L). Resistance to linezolid and vancomycin for enterococci and to penicillin for streptococci appears to be independent of reduced susceptibility to daptomycin. On the other hand, daptomycin was also active against meticillin-resistant Staphylococcus aureus (MIC50 = 0.44 mg/L and MIC90 = 0.78 mg/L) and meticillin-resistant coagulase-negative staphylococci (MIC50 = 0.24 mg/L and MIC90 = 0.44 mg/L); however, 0.9% of the staphylococci tested had an MIC > 1mg/L, which is the Clinical and Laboratory Standards Institute breakpoint proposed for susceptibility. For all tested organism groups, resistance to daptomycin was not associated with glycopeptide resistance.
authors.affiliation: Department of Microbiology, University Hospital of Larissa, Larissa, Greece.
authors.forename: E
authors.initials: E
authors.lastname: Malli
authors.forename: I
authors.initials: I
authors.lastname: Spiliopoulou
authors.forename: F
authors.initials: F
authors.lastname: Kolonitsiou
authors.forename: D
authors.initials: D
authors.lastname: Klapsa
authors.forename: E
authors.initials: E
authors.lastname: Giannitsioti
authors.forename: K
authors.initials: K
authors.lastname: Pantelidi
authors.forename: A
authors.initials: A
authors.lastname: Pratti
authors.forename: M
authors.initials: M
authors.lastname: Panopoulou
authors.forename: S
authors.initials: S
authors.lastname: Grapsa
authors.forename: E
authors.initials: E
authors.lastname: Alepopoulou
authors.forename: I
authors.initials: I
authors.lastname: Neonakis
authors.forename: F
authors.initials: F
authors.lastname: Frantzidou
authors.forename: S
authors.initials: S
authors.lastname: Alexiou-Daniel
authors.forename: D
authors.initials: D
authors.lastname: Bakola
authors.forename: C
authors.initials: C
authors.lastname: Koutsia-Carouzou
authors.forename: H
authors.initials: H
authors.lastname: Malamou-Lada
authors.forename: L
authors.initials: L
authors.lastname: Zerva
authors.forename: E
authors.initials: E
authors.lastname: Vlahaki
authors.forename: S
authors.initials: S
authors.lastname: Kartali-Ktenidou
authors.forename: E D
authors.initials: ED
authors.lastname: Anastassiou
authors.forename: E
authors.initials: E
authors.lastname: Petinaki
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017576:Daptomycin / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial / Q000235:genetics; D016521:Electrophoresis, Gel, Pulsed-Field; D005798:Genes, Bacterial / Q000187:drug effects; D016908:Gram-Positive Bacterial Infections / Q000382:microbiology*; D006095:Gram-Positive Cocci / Q000187:drug effects*; D006115:Greece; D006801:Humans; D008826:Microbial Sensitivity Tests
chemical_list: D000900:Anti-Bacterial Agents; D017576:Daptomycin